Tamorie Smith, MD
Nephrology · Columbus, GANPI 1215140496
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,379 of the $3,765 with a category attached, or 89.8%. It is spread thinly across 22 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.
Across 167 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$704
- Mallinckrodt Hospital Products Inc.$451
- Akebia Therapeutics Inc$323
- Otsuka America Pharmaceutical, Inc.$277
- Baxter Healthcare$252
- OPKO Pharmaceuticals, LLC$189
- plus $2K from 16 others
Across 250 payments — averaging $7490.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.5M
- Medtronic$141K
- Vertex$106K
- Akebia Therapeutics Inc$55K
- Takeda Pharmaceuticals U.S.A., Inc.$32K
What the payments were for
- Food & beverage$3,37990%
- Education$38610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 32 | $704 |
| Mallinckrodt Hospital Products Inc. | 10 | $451 |
| Akebia Therapeutics Inc | 15 | $323 |
| Otsuka America Pharmaceutical, Inc. | 11 | $277 |
| Baxter Healthcare | 6 | $252 |
| OPKO Pharmaceuticals, LLC | 11 | $189 |
| Novo Nordisk | 12 | $175 |
| Vifor Pharma, Inc. | 4 | $173 |
| Bayer | 8 | $172 |
| Amgen(2 entities) | 7 | $171 |
| Travere Therapeutics, Inc. | 19 | $166 |
| GSK | 5 | $146 |
| Novartis | 5 | $109 |
| Calliditas Therapeutics US Inc. | 5 | $102 |
| Ardelyx, Inc. | 4 | $94 |
| Cormedix Inc. | 2 | $64 |
| Fresenius USA Marketing, Inc. | 3 | $55 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,765 in reported general payments places this provider in the 70th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 14 | $71,563 |
| FarxigaDapagliflozin Propanediol | 52 | $62,483 |
| AuryxiaFerric Citrate | 19 | $55,137 |
| JardianceEmpagliflozin | 67 | $51,582 |
| RayaldeeCalcifediol | 33 | $48,671 |
| KerendiaFinerenone | 35 | $33,777 |
| Sevelamer Carbonate | 82 | $30,582 |
| OzempicSemaglutide | 17 | $23,803 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $12,561 |
| JanuviaSitagliptin Phosphate | 17 | $9,942 |
| EliquisApixaban | 11 | $8,999 |
| LinzessLinaclotide | 11 | $6,906 |
| Calcitriol | 276 | $5,393 |
| Nifedipine ErNifedipine | 148 | $4,568 |
| Midodrine Hcl | 35 | $3,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $704 | $75,04469 claims |
| Akebia Therapeutics IncAuryxia | $323 | $55,13719 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $189 | $48,67133 claims |
| BayerKerendia | $172 | $33,77735 claims |
| Novo NordiskOzempic | $175 | $23,80317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 nephrology providers in Georgia.
Other nephrology in Columbus
- Rajendran AlappanColumbus$87K
- Rajeev ChauhanColumbus$32K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.